Cervarix™

BIOLOGICAL6 trials

Conditions

Cervical Intraepithelial NeoplasiaInfections, PapillomavirusPapillomavirus Type 16/18 InfectionPapillomavirus Vaccines

Phase 2

Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America

CompletedNCT00546078

GlaxoSmithKlineInfections, Papillomavirus

Start: 2008-01-14End: 2009-12-01Updated: 2018-06-26

Phase 3

Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18

CompletedNCT00122681

GlaxoSmithKlineInfections, Papillomavirus

Start: 2004-05-06End: 2009-11-26Updated: 2018-08-20

Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation.

CompletedNCT00250276

GlaxoSmithKlineInfections, Papillomavirus, Papillomavirus Vaccines

Start: 2005-10-28End: 2007-03-01Updated: 2020-01-02

Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women

CompletedNCT00337818

GlaxoSmithKlineCervical Intraepithelial Neoplasia, Papillomavirus Type 16/18 Infection

Start: 2006-06-30End: 2009-01-31Updated: 2017-05-30

Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects

CompletedNCT00578227

GlaxoSmithKlineInfections, Papillomavirus

Start: 2007-12-15End: 2009-04-28Updated: 2018-08-17

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus Vaccine (Cervarix™) When Co-administered With GSK Biologicals' Hepatitis A Vaccine (Havrix®) in Healthy Female Adolescents Aged 9-14 Years

WithdrawnNCT02082639

GlaxoSmithKlineInfections, Papillomavirus

Start: 2015-02-28End: 2015-11-30Updated: 2015-07-20

Frontiers in Cellular and Infection Microbiology2024-09-093 citations

Lack of detectable HPV18 antibodies in 14% of quadrivalent vaccinees in a longitudinal cohort study.

2024-08-132 citations

EP097/#28 Immunogenicity of AS04-adjuvanted vaccine in females with existing high-risk HPV infection at first vaccination: pooled analysis of individual data from four large clinical trials worldwide

2023-11-01

Progression from human papillomavirus (HPV) infection to cervical lesion or clearance in women (18–25 years): Natural history study in the control arm subjects of AS04-HPV-16/18 vaccine efficacy study in China between 2008 and 2016

Expert Review of Vaccines2021-12-2315 citations

Human papillomavirus vaccine efficacy against invasive, HPV-positive cancers: population-based follow-up of a cluster-randomised trial

BMJ Open2021-12-0143 citations

Efficacy of the AS04-adjuvanted HPV-16/18 vaccine in young Chinese women with oncogenic HPV infection at baseline: post-hoc analysis of a randomized controlled trial

Human Vaccines & Immunotherapeutics2020-11-1217 citations

Prevalence and Incidence of Human Papillomavirus (HPV) Infection Before and After Pregnancy: Pooled Analysis of the Control Arms of Efficacy Trials of HPV-16/18 AS04-Adjuvanted Vaccine

Open Forum Infectious Diseases2019-12-0113 citations

Efficacy of the AS04-Adjuvanted HPV16/18 Vaccine: Pooled Analysis of the Costa Rica Vaccine and PATRICIA Randomized Controlled Trials

JNCI Journal of the National Cancer Institute2019-11-0532 citations

Is the risk of cervical atypia associated with the interval between menarche and the start of sexual activity? A population-based cohort study

BMJ Open2019-09-017 citations

Risk of newly detected infections and cervical abnormalities in adult women seropositive or seronegative for naturally acquired HPV‐16/18 antibodies

Cancer Medicine2019-07-0518 citations

A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years

Human Vaccines & Immunotherapeutics2019-07-0357 citations

Risk of HPV-16/18 Infections and Associated Cervical Abnormalities in Women Seropositive for Naturally Acquired Antibodies: Pooled Analysis Based on Control Arms of Two Large Clinical Trials

The Journal of Infectious Diseases2018-04-1229 citations

Ten-year immune persistence and safety of the HPV-16/18 AS04-adjuvanted vaccine in females vaccinated at 15-55 years of age.

2017-10-0552 citations

Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point—registry-based follow-up of <i>three cohorts from randomized trials</i>

BMJ Open2017-08-0188 citations

Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials.

2017-01-2842 citations

Prior human papillomavirus‐16/18 AS04‐adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: <i>Post‐hoc</i> analysis from a randomized controlled trial

International Journal of Cancer2016-08-19100 citations

Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9–14 Years Versus a 3-Dose Regimen in Women Aged 15–25 Years

The Journal of Infectious Diseases2016-02-0346 citations

Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study

Human Vaccines & Immunotherapeutics2015-07-1593 citations

Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.

2015-06-09222 citations

Efficacy of Human Papillomavirus 16 and 18 (HPV-16/18) AS04-Adjuvanted Vaccine against Cervical Infection and Precancer in Young Women: Final Event-Driven Analysis of the Randomized, Double-Blind PATRICIA Trial

Clinical and Vaccine Immunology2015-02-05118 citations

23 more papers not shown

Cervarix™

Sponsors

Conditions

Phase 2

Phase 3

Related Papers